Quick Answer
Medicenna Therapeutics Corp. reported Total Assets of $36.45 million for fiscal year 2023.
Medicenna Therapeutics Corp. — Key Financials by Year
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Total Assets | $36.45M +55.4% |
$23.46M -44.5% |
$42.25M | — |
| R&D Expense | $9.30M -36.8% |
$14.72M +35.4% |
$10.87M +85.2% |
$5.87M |
- Medicenna Therapeutics Corp. reported Total Assets of $36.45 million for fiscal year 2023.
- Medicenna Therapeutics Corp. showed an increase of +55.4% in Total Assets compared to the prior fiscal year.
- Medicenna Therapeutics Corp. reported R&D Expense of $9.30 million for fiscal year 2023.
- Medicenna Therapeutics Corp. showed a decrease of -36.8% in R&D Expense compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: